IPCA Laboratories Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹677.55
- Today's High:
- ₹685.9
- Open Price:
- ₹682.45
- 52W Low:
- ₹670
- 52W High:
- ₹1028.7404
- Prev. Close:
- ₹681.7
- Volume:
- 171129
Company Statistics
- Market Cap.:
- ₹173.43 billion
- Book Value:
- 227.667
- Revenue TTM:
- ₹60.22 billion
- Operating Margin TTM:
- 11.53%
- Gross Profit TTM:
- ₹36.23 billion
- Profit Margin:
- 8.72%
- Return on Assets TTM:
- 14.04%
- Return on Equity TTM:
- 25.46%
Company Profile
IPCA Laboratories Limited had its IPO on under the ticker symbol IPCALAB.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. IPCA Laboratories Limited has a staff strength of 15,155 employees.
Stock update
Shares of IPCA Laboratories Limited opened at ₹682.45 at the start of the last trading session i.e. 2023-05-28.
The stocks traded within a range of ₹677.55 - ₹685.9, and closed at ₹684.45.
This is a +0.4% increase from the previous day's closing price.
A total volume of 171,129 shares were traded at the close of the day’s session.
In the last one week, shares of IPCA Laboratories Limited have increased by +1.38%.
IPCA Laboratories Limited's Key Ratios
IPCA Laboratories Limited has a market cap of ₹173.43 billion, indicating a price to book ratio of 3.7935 and a price to sales ratio of 3.7514.
In the last 12-months IPCA Laboratories Limited’s revenue was ₹60.22 billion with a gross profit of ₹36.23 billion and an EBITDA of ₹9.27 billion. The EBITDA ratio measures IPCA Laboratories Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, IPCA Laboratories Limited’s operating margin was 11.53% while its return on assets stood at 14.04% with a return of equity of 25.46%.
In Q4, IPCA Laboratories Limited’s quarterly earnings growth was a negative -45.2% while revenue growth was a positive 8.1%.
IPCA Laboratories Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 33.0082
- PEG
Its diluted EPS in the last 12-months stands at ₹20.71 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into IPCA Laboratories Limited’s profitability.
IPCA Laboratories Limited stock is trading at a EV to sales ratio of 3.6275 and a EV to EBITDA ratio of 18.5539. Its price to sales ratio in the trailing 12-months stood at 3.7514.
IPCA Laboratories Limited stock pays annual dividends of ₹4 per share, indicating a yield of 0.59% and a payout ratio of 25.7%.
Balance sheet and cash flow metrics
- Total Assets
- ₹78.98 billion
- Total Liabilities
- ₹13.85 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 25.7%
IPCA Laboratories Limited ended 2023 with ₹78.98 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹78.98 billion while shareholder equity stood at ₹57.78 billion.
IPCA Laboratories Limited ended 2023 with ₹0 in deferred long-term liabilities, ₹13.85 billion in other current liabilities, 253700000.00 in common stock, ₹57.53 billion in retained earnings and ₹541.60 million in goodwill. Its cash balance stood at ₹3.87 billion and cash and short-term investments were ₹14.57 billion. The company’s total short-term debt was ₹0 while long-term debt stood at ₹4.33 billion.
IPCA Laboratories Limited’s total current assets stands at ₹45.54 billion while long-term investments were ₹0 and short-term investments were ₹2.65 billion. Its net receivables were ₹11.03 billion compared to accounts payable of ₹5.76 billion and inventory worth ₹18.23 billion.
In 2023, IPCA Laboratories Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, IPCA Laboratories Limited paid ₹0.26 in dividends in 2023.
Other key metrics
- Current Trading Price
- ₹684.45
- 52-Week High
- ₹1028.7404
- 52-Week Low
- ₹670
- Analyst Target Price
- ₹
IPCA Laboratories Limited stock is currently trading at ₹684.45 per share. It touched a 52-week high of ₹1028.7404 and a 52-week low of ₹1028.7404. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹755.11 and 200-day moving average was ₹845.76 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 4666.3% of the company’s stock are held by insiders while 4068.2% are held by institutions.
Frequently Asked Questions About IPCA Laboratories Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.